Aurobindo Pharma Extinguishes 54,23,728 Equity Shares Under ₹800 Crore Buyback Programme

Aurobindo Pharma Limited has formally completed the extinguishment of 54,23,728 fully paid-up equity shares of ₹1/- face value each, as part of its buyback programme conducted through the tender offer route. The extinguishment was executed on May 14, 2026, and the company notified the stock exchanges on May 15, 2026, in compliance with Regulations 11 and 24(iv) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018.

Buyback Programme Overview

The buyback was carried out at a price of ₹1,475 per equity share, for an aggregate amount not exceeding ₹800,00,00,000 (Rupees Eight Hundred Crore only), on a proportionate basis through the tender offer route. The tendering period opened on Thursday, April 23, 2026, and closed on Wednesday, April 29, 2026 (both days inclusive). The process was initiated pursuant to the Public Announcement dated Tuesday, April 7, 2026, published on Wednesday, April 8, 2026, and the Letter of Offer dated Tuesday, April 21, 2026.

Share Capital Reconciliation

The extinguishment of 54,23,728 equity shares — all in dematerialised form — has resulted in a reduction in the company's issued, subscribed, and fully paid-up share capital. The following table presents the pre- and post-extinguishment share capital position:

Particulars: No. of Equity Shares Amount (in ₹) Pre-extinguishment paid-up capital 58,08,01,623 Equity Shares of ₹1/- each 58,08,01,623 Less: Shares bought back (Dematerialised Form) 54,23,728 54,23,728 Less: Shares bought back (Physical Form) Nil Nil Post-extinguishment paid-up capital 57,53,77,895 Equity Shares of ₹1/- each 57,53,77,895

Depository Confirmations

Confirmations of the extinguishment were received from both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) on May 14, 2026. NSDL confirmed the debit of 5,423,728.000 equity shares (ISIN: INE406A01037) from the company's account held with Stock Holding Corporation of India Limited (DP ID: IN301330, Client ID: 40630602), with an execution date of May 13, 2026. CDSL similarly confirmed the buyback of 5423728 equity shares, noting that the capital of the company after the buyback as recorded with CDSL stands at Rs. 575377895/- (Equity Shares of Rs.1/- each).

Shareholding Pattern: Pre and Post Buyback

The extinguishment has resulted in a marginal shift in the shareholding pattern of the company. The table below presents the pre- and post-buyback shareholding distribution:

Category: Pre-Buyback Shares Pre-Buyback (%) Post-Buyback Shares Post-Buyback (%) Promoter & Promoter Group and persons acting in concert 30,09,48,721 51.82 29,85,22,726 51.88 Non-Promoter Shareholding 27,98,52,902 48.18 27,68,55,169 48.12 — Foreign Investors (OCBs/FIIs/NRIs/Non-residents/Non-domestic companies) 9,06,24,695 15.60 — — — Indian Financial Institutions/Banks/Mutual Funds/Government Companies 14,50,76,920 24.98 — — — Others (Individuals, Bodies Corporate, Employees, etc.) 4,41,51,287 7.60 — — Total 58,08,01,623 100.00 57,53,77,895 100.00

Pre-buyback figures are as on the Record Date. Post-buyback figures reflect extinguishment of 54,23,728 equity shares accepted in the Buyback.

Regulatory Compliance and Certification

A certificate of extinguishment dated May 15, 2026, was issued in compliance with Regulation 11(iii) of the Buyback Regulations, signed by the Managing Director K. Nithyananda Reddy, Whole-time Director M. Madan Mohan Reddy, and Company Secretary & Compliance Officer B. Adi Reddy. The certificate was also attested by the Secretarial Auditor, MRR & Associates, Company Secretaries, and KFin Technologies Limited, the Registrar to the Buyback. Axis Capital Limited served as the Manager to the Buyback. The company has submitted copies of the depository confirmation letters, the extinguishment certificate, and the pre- and post-buyback shareholding pattern to the stock exchanges as required under the applicable regulations.

Aurobindo Pharma has disclosed, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Hon'ble High Court of Telangana, Hyderabad, passed an order dated May 6, 2026, dismissing a writ petition filed by certain members of its promoter and promoter group. The order was received by the company on May 15, 2026, and the intimation was filed on May 16, 2026.

Background of the Settlement Proceedings

The matter traces its origins to a settlement application filed by the petitioners with SEBI under the SEBI (Settlement) Regulations, 2018, in relation to alleged violations of Regulations 3 and 4 read with Regulation 12(2) of the SEBI (Prohibition of Insider Trading) Regulations, 1992. SEBI passed a settlement order on May 6, 2020, in response to this application.

Subsequently, on October 23, 2020, SEBI issued a communication directing the petitioners to deposit profits made from trading in the shares of the company, along with applicable interest, into the Investor Protection and Education Fund (IPEF) within 15 calendar days. The petitioners challenged this communication by filing a writ petition before the Hon'ble High Court of Telangana, Hyderabad.

Key Details of the Court Order

The following table summarises the key particulars of the regulatory order as disclosed by the company:

Parameter: Details Authority: Hon'ble High Court of Telangana, at Hyderabad Order Date: May 6, 2026 Date of Receipt: May 15, 2026 Nature of Order: Dismissal of Writ Petition Profits to be Deposited: Rs. 6.53 crores Interest Rate Directed by SEBI: 12% per annum from date of violation till date of filing of revised settlement terms Deposit Destination: Investor Protection and Education Fund (IPEF) Impact on Company Financials/Operations: None

Petitioners and Their Relationship to the Company

The individuals and entity named in the proceedings are members of the promoter and promoter group of Aurobindo Pharma:

Mr. P. V. Ramprasad Reddy — Promoter of the company

Ms. P. Suneela Rani — Member of the promoter group

Mr. Kambam Prasad Reddy — Member of the promoter group

Trident Chemphar Limited — Member of the promoter group

Company's Stated Position and Next Steps

Aurobindo Pharma has clarified that since the order is directed against the petitioners in their individual or associated capacities, it has no impact on the company's financials, operations, or other activities. The petitioners, in consultation with their respective legal advisors, are stated to be evaluating the future course of action following the dismissal of the writ petition. The company's disclosure was digitally signed by B. Adi Reddy, Company Secretary, on May 16, 2026.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.